Tyrosine Kinase Inhibitor Market
Global Tyrosine Kinase Inhibitor Market Size, Share and Trends Analysis Report by Type (BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, and Others), by Application (Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, and Others) Forecast Period (2022-2028) Update Available - Forecast 2024-2030
The global tyrosine kinase inhibitor market is expected to rise at a substantial CAGR during the forecast period. A tyrosine kinase inhibitor (TKI) is a type of targeted therapy that involves taking a pharmaceutical medicine orally. It targets and kills certain types of cancer cells while causing minimal harm to healthy cells. It is additionally, responsible for signal transduction cascades activating several proteins. Lapatinib, that has been approved by the FDA for use in combination with chemotherapy or hormone therapy, is currently being tested in clinical trials for the treatment of HER2-positive breast cancers. The major factors that are accelerating the growth of the market include increasing prevalence of cancer incidence and rising demand for novel treatments. Key players and researchers are investing to develop new and advanced tyrosine kinase inhibitors with less toxicity and adverse effects, this factor is likely to aid in the market growth and would offer new growth opportunities.
However, high development costs result in a higher drug's market price after approval. As a result, the drug's price has restrained the market's expansion to some extent.
Impact of COVID-19 on Global Tyrosine Kinase Inhibitor Market.
The Covid-19 has raised the demand for tyrosine kinase inhibitor. Cancer patients have been identified as one of the most vulnerable populations for COVID-19, with a high fatality rate thus far. Patients with lung cancer, myeloma, leukemia, lymphoma, and metastatic cancer, in particular, had the highest rate of severe COVID-19 problems, that were defined as illness necessitating admission to an ICU, mechanical ventilation, or death. For example, in a limited cohort of COVID-19 infected patients, Bruton tyrosine kinase (BTK) inhibitors such ibrutinib and acalabrutinib showed a protective effect against pulmonary damage. These factors raised the demand for tyrosine kinase inhibitors hence rises the growth of the tyrosine kinase inhibitor market globally.
Segmental Outlook
The Global Tyrosine Kinase Inhibitor market is segmented based on type and application. Based on type, the market is sub-segmented into BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, and Others. Among these, VEGFR tyrosine kinase inhibitors are projected to grow more during the forecast period. Based on application the market is sub-segmented into Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, and Others.
**The above-mentioned segments can be customized as per the requirements.
Global Tyrosine Kinase Inhibitor Market Share by Type, 2021(%)
BCR-ABL Tyrosine Kinase Inhibitor Segment is Expected to Hold Prominent Share in the Global Tyrosine Kinase Inhibitor market.
Based on type, BCR-ABL Tyrosine Kinase Inhibitor has seen an increase in market share. For Instance,
Imatinib is a drug that is used to treat some types of leukemia (cancer that starts in the white blood cells) additionally, other malignancies and blood cell abnormalities. Moreover, the inhibitor is primarily used in the treatment of chronic myeloid leukemia. Among BCR-ABL Tyrosine Kinase Inhibitor, Imatinib was the first BCR - ABL inhibitor, which was approved by FDA in 2001 as first-line therapy for chronic myeloid leukemia. With further advancements in the management of chronic myeloid leukemia along with its increasing prevalence, the demand for BCR-ABL Tyrosine Kinase Inhibitor is expected to increase more lead to the market growth.
Regional Outlooks
The global tyrosine kinase inhibitor market is further segmented based on geography Including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East and Africa, and Latin America).
**The market can be analyzed for a particular region or country level as per the requirement.
Global Tyrosine Kinase Inhibitor Market Growth, by Region 2022-2028
North America is expected to dominate the Global Tyrosine Kinase Inhibitor market.
Geographically, the North America region is projected to hold the prominent market share during the forecast period. The US and Canada are the major economies contributing to the market growth. The US has one of the highest cancer rates in the world. TKIs are used to treat cancer, therefore the rising prevalence of the disease will boost the market growth. For example, Ocular Therapeutix, Inc. dosed the first patient in Phase 1 clinical study of OTX-TKI (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration in the US in July 2021. As a result, the current clinical trial process in the target market will strengthen the market under consideration. As a result, the market is likely to grow further as strong demand is matched by the presence of global companies in the region.
Market Players Outlook
The major companies serving the Global Tyrosine Kinase Inhibitor market include Novartis International AG, AstraZeneca plc, Pfizer Inc., Bayer AG, F. Hoffmann-La Roche AG, and others. To enhance their market share, industry participants are employing a number of critical techniques. For example, Pfizer Inc. got FDA clearance for a supplemental New Drug Application (sNDA) for LORBRENA (lorlatinib), a TKI, in March 2021, increasing the indication to cover first-line therapy of persons with ALK-positive non-small cell lung cancer (NSCLC). Adults with metastatic NSCLC whose tumors are ALK-positive as determined by an FDA-approved test should take LORBRENA.
The Report Covers
- Market value data analysis of 2022 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global tyrosine kinase inhibitor market. Based on the availability of data, information related to new product launches, and relevant news is additionally available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on The Global Tyrosine Kinase Inhibitor Market
• Recovery Scenario of Global Tyrosine Kinase Inhibitor Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Novartis International AG
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. AstraZeneca plc
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Pfizer Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. Swot Analysis
3.3.4. Recent Developments
3.4. Bayer AG
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. F. Hoffmann-La Roche AG
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Tyrosine Kinase Inhibitor Market by Type
4.1.1. BCR-ABL Tyrosine Kinase Inhibitor
4.1.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
4.1.3. Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
4.1.4. Others
4.2. Global Tyrosine Kinase Inhibitor Market by Application
4.2.1. Chronic Myeloid Leukemia (CML)
4.2.2. Lung Cancer
4.2.3. Breast Cancer
4.2.4. Renal Cell Cancer
4.2.5. Others
5. Regional Analysis
5.1. North America
5.1.1 United States
5.1.2 Canada
5.2. Europe
5.2.1.UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. AstraZeneca plc
6.2. Astellas Pharma US, Inc.
6.3. Biogen Inc.
6.4. Bristol Myers Squibb
6.5. Boehringer Ingelheim International GmbH,
6.6. Eisai Co., Ltd.
6.7. Eurofarma Laboratórios S.A.
6.8. Genentech Inc
6.9. GlaxoSmithKline plc.
6.10. Johnson & Johnson Services, Inc.
6.11. Merck & Co., Inc.
6.12. Ocular Therapeutix, Inc.
6.13. Sanofi S.A.
6.14. Tolero Pharmaceutical
1. GLOBAL TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL BCR-ABL TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR (VEGFR) TYROSINE KINASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL OTHERS TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028($ MILLION)
7. GLOBAL TYROSINE KINASE INHIBITOR MARKET IN CHRONIC MYELOID LEUKEMIA (CML) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
8. GLOBAL TYROSINE KINASE INHIBITOR MARKET IN LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
9. GLOBAL TYROSINE KINASE INHIBITOR MARKET IN BREAST CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
10. GLOBAL TYROSINE KINASE INHIBITOR MARKET IN RENAL CELL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
11. GLOBAL TYROSINE KINASE INHIBITOR MARKET IN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
12. GLOBAL TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028($ MILLION)
13. NORTH AMERICAN TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
14. NORTH AMERICAN TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
15. NORTH AMERICAN TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
16. EUROPEAN TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. EUROPEAN TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028($ MILLION)
18. EUROPEAN TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
21. ASIA-PACIFIC TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
22. REST OF THE WORLD TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
23. REST OF THE WORLD TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
24. REST OF THE WORLD TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL TYROSINE KINASE INHIBITOR MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL TYROSINE KINASE INHIBITOR MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL TYROSINE KINASE INHIBITOR MARKET, 2021-2028 (%)
4. GLOBAL TYROSINE KINASE INHIBITOR MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL BCR-ABL TYROSINE KINASE INHIBITOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR (VEGFR) TYROSINE KINASE INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL OTHER TYROSINE KINASE INHIBITOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL TYROSINE KINASE INHIBITOR MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
10. GLOBAL TYROSINE KINASE INHIBITOR MARKET IN CHRONIC MYELOID LEUKEMIA (CML) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL TYROSINE KINASE INHIBITOR MARKET IN LUNG CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL TYROSINE KINASE INHIBITOR MARKET IN BREAST CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL TYROSINE KINASE INHIBITOR MARKET IN RENAL CELL CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL TYROSINE KINASE INHIBITOR MARKET IN OTHER APPLICATIONS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL TYROSINE KINASE INHIBITOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. US TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
17. CANADA TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
18. UK TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
19. FRANCE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
20. GERMANY TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
21. ITALY TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
22. SPAIN TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
23. REST OF EUROPE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
24. INDIA TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
25. CHINA TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
26. JAPAN TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
27. SOUTH KOREA TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF ASIA-PACIFIC TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
29. REST OF THE WORLD TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
